StarZero All shows Try the podcast clipper →

BillionToOne

also referred to as: billion to one

14 statements across 1 episodes · 7 bullish · 0 bearish · 3 people on the record · first statement Apr 6, 2026 by Ozan Bilgen · said 23 times in 1 episodes since 2026 · across every show →

Mentions by year

brought up most by Jared Friedman (15), David Tsao (7), Ozan Bilgen (1)

tap a year for its mentions
001312512026episodesmentions
0112026episodes it came up in
00130.52512026episodesmentions per episode
2026 23 mentions in 1 episode

every mention, scene by scene, with the transcript →

Everything said about BillionToOne, oldest first

Apr 6, 2026 neutral
Disclosure
Bilgen: Founders planned three-stage expansion from prenatal to early-stage cancer
“One year into the company, it is actually laid out that, you know, we would start at prenatal genetics, then go into late stage cancers, and then go into early stage cancers in this way.”
Ozan Bilgen Apr 6, 2026 ▶ 13:16 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026
Disclosure
Bilgen: BillionToOne had only one doctor ordering tests two months post-launch
“Launched in June, only person that is using the test, you know, two months later is this one Physician, and who is sending, like, maybe one or two tests per week.”
Ozan Bilgen Apr 6, 2026 ▶ 8:06 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 bullish
Assertion Supported
Bilgen: Fetal and tumor cell-free DNA are fundamentally identical to detect
“And, you know, we realized that, you know, fundamentally there is nothing different about, you know, cell-free fetal DNA and cell-free tumor DNA, and the same technology can be applied to both of them.”
Ozan Bilgen Apr 6, 2026 ▶ 13:30 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 neutral
Assertion Supported
Friedman: Most genetic abnormalities previously required invasive amniocentesis for detection
“Before Billion to One, most genetic abnormalities could only be detected via amniocentesis, an invasive procedure that is only used in high-risk pregnancies.”
Jared Friedman Apr 6, 2026 ▶ 3:04 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 positive
Insight
Bilgen: Interdisciplinary scientists accelerate R&D by an order of magnitude
“We have found that having that iterative cycle within one scientist actually accelerates the work that they do by an order of magnitude.”
Ozan Bilgen Apr 6, 2026 ▶ 15:40 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 positive
Assertion Not checkable as stated
Tsao: NorthStar Select found actionable cancer targets missed by tissue biopsy
“We ended up testing this person using our North Star Select test. We identified that this person was eligible for A therapy called immunotherapy based on identifying microsatellite instability in the tumor DNA that was in that patient's bloodstream, and this w…”
David Tsao Apr 6, 2026 ▶ 14:30 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 bullish
Prediction Open · timeframe Apr 2029
Bilgen: Current facility can scale to nearly two million tests annually
“We believe that we can expand into close to two million tests per year just using this facility. That would be, you know, around essentially every one in three babies that would be tested with our tests.”
Ozan Bilgen Apr 6, 2026 ▶ 11:36 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026
Disclosure
Bilgen: Small R&D teams own products and report directly to co-founders
“We actually have very small you know, research teams. It is essentially principal investigators, like a scientist who is interdisciplinary, who has a small team of, you know, two or three research associates, and they all directly report to David and me, and t…”
Ozan Bilgen Apr 6, 2026 ▶ 15:51 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 bullish
Assertion Supported
Bilgen: BillionToOne Processes Over 600,000 Tests Annually With ~20% Market Share
“We are processing more than 600,000 tests a year, and in terms of the overall market share, We are close to 20% market share there.”
Ozan Bilgen Apr 6, 2026 ▶ 2:32 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026
Disclosure
Bilgen: BillionToOne raised initial $300,000 in $10k checks over six months
“First 300,000 dollars that, you know, I've raised was, you know, really, really difficult. It took, you know, six months, and it was, you know, 10,000 dollars at a time”
Ozan Bilgen Apr 6, 2026 ▶ 7:50 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 neutral
What-if
Bilgen: Starting in oncology would have made initial commercialization far harder
“Because if we started, I think, on the oncology side, it would have been far more difficult to achieve that initial successful commercialization that gave us more resources to be able to build, you know, new tests and improve the existing tests.”
Ozan Bilgen Apr 6, 2026 ▶ 13:42 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026
Assertion Not checkable as stated
Bilgen: Direct early cancer detection requires raising over $1B pre-revenue
“If you wanted to solve early detection from the very beginning without having this step-by-step approach, you would have to raise more than a billion dollars, you know, without generating a single dollar of revenue.”
Ozan Bilgen Apr 6, 2026 ▶ 19:06 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 positive
Assertion Partly supported
Friedman: BillionToOne Went Public at Over $4 Billion Valuation
“Late last year, they took the company public at a valuation over four billion dollars.”
Jared Friedman Apr 6, 2026 ▶ 2:23 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Apr 6, 2026 positive
Disclosure
Bilgen: Synthetic DNA removes PCR amplification noise from sequencing data
“So what we have done is to add a synthetic DNA into the patient sample that we get before any amplification happens. These synthetic DNA Allow us to know how much amplification happened at different genomic locations. You know, what are the errors that are bei…”
Ozan Bilgen Apr 6, 2026 ▶ 3:51 BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 300 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more